Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E97.85 EPS (ttm)3.49 Insider Own0.30% Shs Outstand101.07M Perf Week-1.79%
Market Cap34.52B Forward P/E27.96 EPS next Y12.21 Insider Trans-3.28% Shs Float74.50M Perf Month10.07%
Income396.30M PEG4.57 EPS next Q2.57 Inst Own75.10% Short Float5.75% Perf Quarter14.49%
Sales2.50B P/S13.81 EPS this Y-43.60% Inst Trans0.05% Short Ratio5.20 Perf Half Y1.95%
Book/sh23.60 P/B14.47 EPS next Y20.45% ROA12.90% Target Price353.28 Perf Year46.97%
Cash/sh8.08 P/C42.25 EPS next 5Y21.44% ROE19.30% 52W Range233.06 - 353.05 Perf YTD24.08%
Dividend- P/FCF67.13 EPS past 5Y42.20% ROI19.20% 52W High-3.23% Beta0.89
Dividend %- Quick Ratio5.20 Sales past 5Y54.60% Gross Margin88.20% 52W Low46.58% ATR8.00
Employees2469 Current Ratio5.50 Sales Q/Q45.50% Oper. Margin34.30% RSI (14)65.75 Volatility1.69% 2.48%
OptionableYes Debt/Eq0.22 EPS Q/Q3.80% Profit Margin15.90% Rel Volume0.44 Prev Close341.51
ShortableYes LT Debt/Eq0.22 EarningsAug 05 BMO Payout0.00% Avg Volume824.62K Price341.63
Recom2.10 SMA202.77% SMA508.85% SMA20013.28% Volume322,095 Change0.04%
06-Aug-14Reiterated RBC Capital Mkts Outperform $349 → $373
21-Jul-14Initiated Argus Buy $375
16-Apr-14Initiated Canaccord Genuity Buy $350
13-Feb-14Downgrade Oppenheimer Outperform → Perform $310 → $325
30-Sep-13Reiterated Oppenheimer Outperform $300 → $310
22-Aug-13Initiated Oppenheimer Outperform $300
17-May-13Initiated UBS Neutral $290
06-May-13Reiterated RBC Capital Mkts Outperform $270 → $286
06-May-13Reiterated Barclays Overweight $275 → $305
02-May-13Reiterated Barclays Overweight $194 → $275
28-Feb-13Initiated Barclays Overweight $194
21-Dec-12Reiterated RBC Capital Mkts Outperform $171 → $190
14-Feb-12Reiterated RBC Capital Mkts Outperform $83 → $130
10-Jan-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
05-Dec-11Reiterated Brean Murray Buy $78 → $67
28-Jul-11Upgrade RBC Capital Mkts Sector Perform → Outperform $70 → $70
09-May-11Reiterated Needham Buy $49 → $60
29-Apr-11Reiterated Barclays Capital Overweight $64 → $72
29-Apr-11Downgrade RBC Capital Mkts Outperform → Sector Perform $70 → $70
28-Apr-11Reiterated RBC Capital Mkts Outperform $48 → $70
21-Aug-14 01:25PM  Qihoo, Regeneron Among 5 Stocks With Top Fundamentals at Investor's Business Daily
01:25PM  Qihoo Among 5 Stocks With Top Fundamentals at Investor's Business Daily
19-Aug-14 10:00AM  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Ring The NASDAQ Stock Market Opening Bell GlobeNewswire
09:30AM  Regeneron Announces Upcoming 2014 Investor Conference Presentations PR Newswire
07:07AM  [video] Hot biotech drugs at CNBC
18-Aug-14 01:46PM  Jazz, Celgene Lead Top 4 Drugmaker Profit Margins at Investor's Business Daily
09:16AM  [video] Cramer: Market about Russia-Ukraine at CNBC
17-Aug-14 10:37PM  Regeneron CEO: How I became a billionaire at CNNMoney.com
14-Aug-14 08:33PM  [video] Eyeball injections equal eye-popping profits at CNNMoney.com
03:10PM  [video] Red hot biotech stocks at CNBC
13-Aug-14 06:08PM  Cramer: Is Street preparing for the worst? at CNBC
12-Aug-14 04:20PM  Regeneron's Eye Drug Eylea Cleared in the EU for DME Zacks
01:04PM  REGENERON PHARMACEUTICALS INC Financials EDGAR Online Financials
11-Aug-14 04:46PM  Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments Benzinga
09:19AM  [video] Cramer's Mad Dash: Tesla breaking out at CNBC
02:30AM  EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME) PR Newswire
07-Aug-14 08:38AM  Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the Day Zacks
06-Aug-14 01:23PM  Celgene: Five Reasons to Be Bullish at Barrons.com
11:00AM  Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress Zacks
05-Aug-14 06:30PM  4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Investor's Business Daily
04:46PM  Ukraine Tension Prominent As Dow Suffers Triple Point Digit Loss; S&P 500 & Nasdaq Also Lower Benzinga
04:46PM  Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower Benzinga
03:30PM  Deutsche Bank Raises Regeneron's Price Target To $425 Benzinga
02:50PM  Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat Zacks
01:05PM  Midday movers: Family Dollar Stores, Target & More at CNBC
10:43AM  Regeneron sales top forecast as Eylea picks up steam Reuters
10:02AM  Why Regeneron (REGN) Stock Is Up Today at TheStreet
08:51AM  Regeneron sales top forecast as Eylea picks up steam Reuters
07:07AM  Q2 2014 Regeneron Pharmaceuticals Earnings Release - Before Market Open CCBN
06:44AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
06:43AM  Regeneron sales top forecast as Eylea delivers Reuters
06:30AM  Regeneron Reports Second Quarter 2014 Financial and Operating Results PR Newswire
04-Aug-14 06:56PM  Cramer: Dozens of stocks that could work higher at CNBC
01:30PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Regeneron Pharmaceuticals, Inc. on Behalf of Shareholders PR Newswire
05:59AM  Sanofi and Regeneron Pay $67.5 Million to Fast-Track a Cholesterol Drug at BusinessWeek
01-Aug-14 04:15PM  Massive, unusual options volume Friday confounds Wall St Reuters
03:05PM  Massive, unusual options volume Friday confounds Wall St Reuters
02:23PM  Unusual options volume seen in Priceline, Regeneron, others Reuters
01:03PM  3 Stocks Pushing The Drugs Industry Higher at TheStreet
10:17AM  Watch For Today's Momo Momentum Stock: Regeneron Pharmaceuticals (REGN) at TheStreet
31-Jul-14 02:12PM  Len Schleifer's Science Focus Pays Off At Regeneron at Investor's Business Daily
07:37AM  [$$] Regeneron Boosted by Latest Approval at Barrons.com
02:41AM  Sanofi lifts 2014 profit forecast as Q2 beats expectations Reuters
01:30AM  Sanofi lifts 2014 guidance after Q2 earnings beat expectations Reuters
01:08AM  [$$] Drug Firms Buy $67.5 Million Voucher to Speed FDA Review at The Wall Street Journal
12:43AM  [$$] Drug Firms Buy $67.5 Million Voucher to Speed FDA Review at The Wall Street Journal
30-Jul-14 10:55PM  [$$] Drug Firms Buy $67.5 Million Voucher to Speed FDA Review at The Wall Street Journal +5.80%
08:43PM  [$$] Drug Firms Buy $67.5 Million Voucher to Speed FDA Review at The Wall Street Journal
07:21PM  [$$] Drug Firms Buy $67.5 Million Voucher to Speed FDA Review at The Wall Street Journal
06:42PM  [$$] BioMarin Sells Priority Review Voucher To Regeneron at The Wall Street Journal
06:00PM  Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema Zacks
05:56PM  [$$] BioMarin Sells Priority Review Voucher To Regeneron at The Wall Street Journal
05:00PM  Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints Reuters
05:00PM  Stocks End Mixed; Akamai Falls, Yelp Rises After Hours at Investor's Business Daily
04:28PM  US STOCKS-S&P 500, Nasdaq end up as Fed in no rush to raise rates Reuters
04:01PM  Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission PR Newswire
03:31PM  US STOCKS-S&P 500 nearly flat as investors digest Fed statement Reuters
02:33PM  US STOCKS-S&P 500 turns higher after Fed statement Reuters
02:32PM  Edwards, Hospira rise as health-care companies see strong earnings at MarketWatch
01:21PM  Rising sales and job cut plan boost Amgen at Financial Times
01:08PM  Amgen, Regeneron rise as health-care companies see strong earnings at MarketWatch
12:45PM  Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints Reuters
12:40PM  [$$] Sanofi, Regeneron's Alirocumab Shows Promise at The Wall Street Journal
11:20AM  Amgen Restructuring Plan, Q2 Earnings Send Stock Up at Investor's Business Daily
11:16AM  Regeneron shares jump after cholesterol drug meets test goals at MarketWatch
10:45AM  Jim Cramer's Mad Dash: Good News for Regeneron at TheStreet
10:31AM  Stocks Thrash Out A Mixed Open; Buffalo Wild Wings Crumples at Investor's Business Daily
09:48AM  Cramer: These 2 biotech stocks are going higher at CNBC
09:42AM  Regeneron Gains as Eye Drug Approved for Expanded Use at Bloomberg
09:21AM  [video] Cramer's Mad Dash: REGN breaks through at CNBC
08:00AM  Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials Reuters
08:00AM  Sanofi Cholesterol Drug Meets Main Goal of 9 Trials at Bloomberg
08:00AM  Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia PR Newswire
08:00AM  Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia PR Newswire
29-Jul-14 07:17PM  FDA Oks expanded use of Regeneron's eye drug Reuters
06:32PM  EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME) PR Newswire
25-Jul-14 11:11AM  Regeneron Pharmaceuticals Inc Stock Upgraded (REGN) at TheStreet
24-Jul-14 05:07PM  Celgene, Alexion Beat Estimates, But Biotechs Fall at Investor's Business Daily
01:03PM  REGN, ILMN And CELG, Pushing Health Care Sector Downward at TheStreet
06:00AM  Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG at TheStreet
23-Jul-14 06:19PM  Aced the SAT? Try this Cramer question at CNBC
02:02PM  5 Novartis Drugs You Need To Know About at Motley Fool
10:54AM  Biogen Idec: Biggest Beat in 10 Years, Largest Leap in Eight Months at Barrons.com
22-Jul-14 04:20PM  Bayer/Regeneron Continue to Progress with Eylea Zacks
21-Jul-14 09:32AM  Coverage initiated on Regeneron Pharms by Argus Briefing.com
18-Jul-14 04:01PM  Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014 PR Newswire
12:41PM  Gilead Sciences: Time For a Dividend? at Barrons.com
10:28AM  InsiderInsights.com Daily Round Up: 7/17/14 at Seeking Alpha
06:00AM  Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision PR Newswire
16-Jul-14 01:04PM  SHPG, REGN And LLY, 3 Drugs Stocks Pushing The Industry Lower at TheStreet
15-Jul-14 12:22PM  InsiderInsights.com Daily Round Up: 7/14/14 at Seeking Alpha
11-Jul-14 03:06PM  Gilead Sciences: The Senate Just Wrote Me a Letter at Barrons.com
10-Jul-14 03:30PM  Sanofi/Regeneron Announce Encouraging Dupilumab Data Zacks
01:46PM  Regeneron's Dupilumab Drug Headed For Phase Three Tests at Investor's Business Daily
10:07AM  Regeneron Picked a Heck of a Day to Announce Good News at Barrons.com
08:20AM  The Zacks Analyst Blog Highlights: Regado Biosciences, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi and Amgen Zacks
06:27AM  Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) at Seeking Alpha
06:00AM  Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM at TheStreet
05:35AM  Valeant Is Hard to Stop TheStreet
09-Jul-14 09:04PM  Regeneron, Sanofi Drug Holds Up in Eczema Study at Motley Fool
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company's antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 23Sale295.935,3691,588,87215,441May 23 03:58 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 22Option Exercise21.2511,200238,00026,641May 23 03:58 PM
POON CHRISTINE ADirectorMay 21Buy291.9025574,435255May 23 10:43 AM
BAKER CHARLES ADirectorMar 24Option Exercise23.8415,000357,60024,000Mar 25 08:03 PM
BAKER CHARLES ADirectorMar 24Sale302.6715,0004,540,0019,000Mar 25 08:03 PM
BROWN MICHAEL SDirectorMar 17Option Exercise33.422,00066,84016,662Mar 18 05:09 PM
BROWN MICHAEL SDirectorMar 17Sale334.292,000668,57314,662Mar 18 05:09 PM
VAGELOS P ROYChairman of the BoardFeb 27Option Exercise12.7070,879899,952140,839Mar 03 09:10 AM
BROWN MICHAEL SDirectorFeb 27Sale335.001,000335,00014,662Feb 27 04:30 PM
BROWN MICHAEL SDirectorFeb 26Option Exercise57.111,00057,11015,662Feb 27 04:30 PM
GOLDSTEIN JOSEPH LDirectorFeb 25Sale338.861,000338,8600Feb 25 05:48 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 25Sale339.5511,8714,030,82363,102Feb 26 04:57 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 24Option Exercise64.9030,2271,961,74685,365Feb 26 04:57 PM
GILMAN ALFRED GDirectorFeb 21Option Exercise18.615,00093,0505,000Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Option Exercise15.8015,000237,000117,772Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Sale339.0015,0005,085,000112,772Feb 24 04:12 PM
GILMAN ALFRED GDirectorFeb 21Sale340.005,0001,700,0000Feb 24 04:12 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 21Sale336.5121,2587,153,60863,102Feb 24 04:11 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 20Option Exercise47.7950,6522,420,80593,102Feb 24 04:11 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 20Option Exercise21.253,00063,7503,000Feb 21 04:43 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale326.991,000326,9891,000Feb 21 04:44 PM
Terifay Robert JSVP CommercialFeb 18Sale332.6812,8654,279,89320,029Feb 19 04:10 PM
Aberman Michael SVP Strategy and Investor RelatFeb 18Sale331.423,6481,209,03615,600Feb 19 04:12 PM
Aberman Michael SVP Strategy and Investor RelatFeb 14Option Exercise30.637,500229,72523,100Feb 19 04:12 PM
Terifay Robert JSVP CommercialFeb 14Option Exercise21.2527,795590,64447,824Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Option Exercise9.1715,000137,550127,772Feb 19 04:11 PM
SING GEORGE LDirectorFeb 14Sale324.0015,0004,860,000112,772Feb 19 04:11 PM
STAHL NEILSVP Research and Development SFeb 13Sale318.8222,6127,209,13624,391Feb 13 06:32 PM
STAHL NEILSVP Research and Development SFeb 12Option Exercise20.0654,5481,094,40664,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Option Exercise89.4515,0001,341,75015,000Feb 13 07:38 PM
SHOOTER ERIC MDirectorFeb 12Sale320.5215,0004,807,8690Feb 13 07:38 PM
GOLDSTEIN JOSEPH LDirectorFeb 12Sale320.621,000320,6202,000Feb 13 04:06 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 12Sale320.3388,98728,504,9851,068,343Feb 13 04:03 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 11Option Exercise9.49189,4631,798,0041,257,806Feb 13 04:03 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Option Exercise30.635,819178,2365,819Feb 12 04:15 PM
GILMAN ALFRED GDirectorFeb 11Option Exercise18.615,00093,0505,000Feb 12 04:17 PM
GILMAN ALFRED GDirectorFeb 11Sale320.005,0001,600,0000Feb 12 04:17 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Sale325.005,8191,891,1750Feb 12 04:15 PM
VAGELOS P ROYChairman of the BoardFeb 11Sale325.1011,4753,730,523103,275Feb 12 04:15 PM
GILMAN ALFRED GDirectorJan 14Option Exercise18.615,00093,0505,000Jan 14 05:25 PM
McCorkle Douglas SVP Controller and Asst TreasurJan 14Sale290.004,0001,160,0000Jan 14 05:26 PM
GILMAN ALFRED GDirectorJan 14Sale300.005,0001,500,0000Jan 14 05:25 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale274.7720,6685,678,96525,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise30.6348,0001,470,24073,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 24Option Exercise21.254,70599,98125,447Dec 26 01:26 PM
Powchik PeterSVP Clinical Development & RegDec 20Sale271.0913336,05520,742Dec 20 05:54 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 19Option Exercise21.254,70599,9811,068,343Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 18Option Exercise21.252956,26921,037Dec 20 05:54 PM
STAHL NEILSVP Research and Development SDec 18Option Exercise21.254,70599,98124,391Dec 19 09:49 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 18Option Exercise21.254,70599,98163,102Dec 19 09:49 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise21.254,70599,98115,441Dec 19 09:48 PM
Terifay Robert JSVP CommercialDec 18Option Exercise21.254,70599,98120,029Dec 19 09:48 PM
Powchik PeterSVP Clinical Development & RegDec 18Sale270.209,0002,431,80020,742Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 17Sale270.0082,16029,742Dec 17 04:16 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise107.1430,6253,281,05638,503Dec 17 04:16 PM
YANCOPOULOS GEORGEPres Regeneron LabsDec 12Option Exercise260.449,5992,499,9641,115,994Dec 13 04:29 PM
VAGELOS P ROYChairman of the BoardDec 02Sale296.119528,1302,257Dec 04 07:34 PM
SING GEORGE LDirectorNov 26Option Exercise15.0110,000150,100122,772Nov 27 04:22 PM
SING GEORGE LDirectorNov 26Sale295.0010,0002,950,000112,772Nov 27 04:22 PM
GOLDSTEIN JOSEPH LDirectorNov 06Sale300.741,000300,7403,000Nov 06 04:17 PM
SCHLEIFER LEONARD SPresident & CEOOct 02Sale313.829,1622,875,25342,087Oct 03 04:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 01Option Exercise111.0129,2763,249,92969,562Oct 03 04:14 PM
BAKER CHARLES ADirectorSep 30Option Exercise19.6915,000295,35024,000Oct 02 04:23 PM
BAKER CHARLES ADirectorSep 30Sale314.0315,0004,710,4399,000Oct 02 04:23 PM
BROWN MICHAEL SDirectorSep 26Option Exercise33.425,000167,10019,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 26Sale309.005,0001,545,00014,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 25Option Exercise33.425,000167,10019,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 25Sale293.645,0001,468,22214,662Sep 27 04:07 PM
SCHLEIFER LEONARD SPresident & CEOSep 19Sale302.67102,94931,159,18142,087Sep 20 04:25 PM
ROBERTS WILLIAMVP Reg Dev & Med SafetySep 18Option Exercise16.8015,000252,00035,644Sep 20 04:24 PM
SCHLEIFER LEONARD SPresident & CEOSep 18Option Exercise9.49218,3892,072,512260,476Sep 20 04:25 PM
ROBERTS WILLIAMVP Reg Dev & Med SafetySep 18Sale304.0015,0004,560,00020,644Sep 20 04:24 PM
Van Plew Daniel PSVP & Gen Mgr IOPSSep 18Sale303.1723,9777,269,04210,736Sep 19 05:16 PM
Van Plew Daniel PSVP & Gen Mgr IOPSSep 17Option Exercise16.8052,500882,00063,236Sep 19 05:16 PM
SCHLEIFER LEONARD SCEO & PresidentSep 09Sale275.475,0001,377,3320Sep 11 04:05 PM
GOLDSTEIN JOSEPH LDirectorAug 23Sale238.291,000238,2904,000Aug 23 05:32 PM
RYAN ARTHUR FDirectorAug 23Sale238.4710,9582,613,15449,855Aug 26 10:26 AM